171 related articles for article (PubMed ID: 37887325)
21. Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.
Kim HJ; Kang SK; Kwon WS; Kim TS; Jeong I; Jeung HC; Kragh M; Horak ID; Chung HC; Rha SY
Int J Cancer; 2018 Jul; 143(1):151-159. PubMed ID: 29435981
[TBL] [Abstract][Full Text] [Related]
22. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma.
Zhu Y; Zhu MX; Zhang XD; Xu XE; Wu ZY; Liao LD; Li LY; Xie YM; Wu JY; Zou HY; Xie JJ; Li EM; Xu LY
Hum Pathol; 2016 Jun; 52():153-63. PubMed ID: 26980013
[TBL] [Abstract][Full Text] [Related]
23. The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy.
Proserpio V; Fittipaldi R; Ryall JG; Sartorelli V; Caretti G
Genes Dev; 2013 Jun; 27(11):1299-312. PubMed ID: 23752591
[TBL] [Abstract][Full Text] [Related]
24. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y
Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609
[TBL] [Abstract][Full Text] [Related]
25. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O
Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881
[TBL] [Abstract][Full Text] [Related]
26. IFITM3 promotes malignant progression, cancer stemness and chemoresistance of gastric cancer by targeting MET/AKT/FOXO3/c-MYC axis.
Chu PY; Huang WC; Tung SL; Tsai CY; Chen CJ; Liu YC; Lee CW; Lin YH; Lin HY; Chen CY; Yeh CT; Lin KH; Chi HC
Cell Biosci; 2022 Aug; 12(1):124. PubMed ID: 35941699
[TBL] [Abstract][Full Text] [Related]
27. High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Wang G; Huang Y; Yang F; Tian X; Wang K; Liu L; Fan Y; Li X; Li L; Shi B; Hao Y; Xia C; Nie Q; Xin Y; Shi Z; Ma L; Xu D; Liu C
Aging (Albany NY); 2020 Feb; 12(3):2030-2048. PubMed ID: 32007952
[TBL] [Abstract][Full Text] [Related]
28. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
29. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.
Kim H; Heo K; Kim JH; Kim K; Choi J; An W
J Biol Chem; 2009 Jul; 284(30):19867-77. PubMed ID: 19509295
[TBL] [Abstract][Full Text] [Related]
30. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
Luo XG; Zhang CL; Zhao WW; Liu ZP; Liu L; Mu A; Guo S; Wang N; Zhou H; Zhang TC
Cancer Lett; 2014 Mar; 344(1):129-137. PubMed ID: 24189459
[TBL] [Abstract][Full Text] [Related]
31. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
Yoshioka Y; Suzuki T; Matsuo Y; Tsurita G; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
Cancer Med; 2017 Jul; 6(7):1665-1672. PubMed ID: 28639750
[TBL] [Abstract][Full Text] [Related]
32. A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.
Peserico A; Germani A; Sanese P; Barbosa AJ; Di Virgilio V; Fittipaldi R; Fabini E; Bertucci C; Varchi G; Moyer MP; Caretti G; Del Rio A; Simone C
J Cell Physiol; 2015 Oct; 230(10):2447-2460. PubMed ID: 25728514
[TBL] [Abstract][Full Text] [Related]
33. Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pathway for gastric cancer metastasis.
Hao NB; Tang B; Wang GZ; Xie R; Hu CJ; Wang SM; Wu YY; Liu E; Xie X; Yang SM
Cancer Lett; 2015 May; 361(1):57-66. PubMed ID: 25727320
[TBL] [Abstract][Full Text] [Related]
34. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D
Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411
[TBL] [Abstract][Full Text] [Related]
35. Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.
Abdel-Rahman O
Expert Rev Anticancer Ther; 2015 Feb; 15(2):235-45. PubMed ID: 25353620
[TBL] [Abstract][Full Text] [Related]
36. SMYD3: a regulator of epigenetic and signaling pathways in cancer.
Bernard BJ; Nigam N; Burkitt K; Saloura V
Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115
[TBL] [Abstract][Full Text] [Related]
37. Metastasis-associated in colon cancer-1 promotes vasculogenic mimicry in gastric cancer by upregulating TWIST1/2.
Wang L; Lin L; Chen X; Sun L; Liao Y; Huang N; Liao W
Oncotarget; 2015 May; 6(13):11492-506. PubMed ID: 25895023
[TBL] [Abstract][Full Text] [Related]
38. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
39. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
Lyu T; Jiang Y; Jia N; Che X; Li Q; Yu Y; Hua K; Bast RC; Feng W
Int J Cancer; 2020 Mar; 146(6):1553-1567. PubMed ID: 31503345
[TBL] [Abstract][Full Text] [Related]
40. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
